Search

In this paper, I will critically assess a very popular interpretation of Heidegger's early thought, according to which meaning (Bedeutung) is conceived as ontologically dependent on human existence (Dasein). To criticize this subjectivist understanding of meaning, I will offer an interpretation of Heidegger's analysis of signs in Being and Time (§17). This will reveal two main things: first, that the ubiquity of sign phenomena is founded on the universality of the structure known as reference (Verweisung); second, that Heidegger's idea of reference offers a non-substantialist understanding of meaning and its relation to the world. [ABSTRACT FROM AUTHOR]

Introducción. La detección de cambios en las características de un proceso aleatorio, cono¬cido como el problema del cambio, se ha convertido en un área de investigación estadística en rápido desarrollo. La correcta y rápida detección de los cambios es relevante en muchas situaciones reales, en particular, en Epidemiología. Materiales y Métodos. Como nueva métrica para determinar el momento efectivo de remisión de una epidemia (momento del cambio), se utiliza el concepto de elasticidad de una distribu¬ción de probabilidad, y se aplica a la reciente pandemia COVID-19 en Chile. Resultados. La aplicación evidencia que existe una demora entre el día “pico”o día con el mayor número de casos, con el de “remisión” identificado por la elasticidad. En ese lapso temporal, entre pico y remisión, no deben suavizarse las medidas de control de la epidemia. Se obtiene una diferencia de 20 días entre los puntos de remisión de las series de contagios y muertes. Esta cifra puede interpretarse como una estimación de la supervivencia para los fallecidos durante la primera ola de COVID-19 una vez detectada en ellos la enfermedad. La comparación de los resultados de la aplicación con la de otros países sudamericanos muestra en ellos idéntico resultado que el observado en Chile, si bien con tiempos de demora entre pico y punto de remisión sensiblemente mayores. Discusión. La medida usada en este trabajo es fácil de comunicar, no exige la formulación previa de hipótesis sobre el comportamiento de los datos y puede ser aplicada en tiempo real, tal y como se van conociendo los datos. Estas características de fácil aplicabilidad e interpretación, generando resultados razonables, la hacen atractiva e interesante para el estudio del cambio en series epidemiológicas.

Introducción: La nefritis lúpica (NL) ocurre en el 50 % de los pacientes con Lupus eritematoso Sistémico. El estándar de tratamiento de inducción consiste en Corticosteroides más inmunosupresores como la Ciclofosfamida o el Micofenolato Mofetilo (MMF). Lograr la remisión se correlaciona con la supervivencia renal a largo plazo. El objetivo del presente estudio fue evaluar la remisión de la NL en pacientes de 18 a 45 años con tratamiento inmunosupresor de inducción para la valoración de la eficacia de la Ciclofosfamida y el MMF. Métodos: se realizó un estudio observacional analítico de cohorte retrospectiva en el Hospital de Especialidades Eugenio Espejo, se contó con un “n” = 185 pacientes con NL, de los cuáles 68 cumplieron los criterios de inclusión. Las variables seleccionadas fueron: sexo, etnia, edad al diagnóstico de lupus y NL, anticuerpos de síndrome antifosfolípido (SAF), SLEDAI-2K, HTA, Clase ISN/RPS, inmunosupresor de inducción, remisión clínica y reactivación, se realizaron pruebas descriptivas e inferenciales con significancia estadística de P < 0.05 en el programa SPSS versión 25. Resultados: Se analizan 68 casos. La NL fue más frecuente en mujeres (95.6%), etnia mestiza (97.1%), con una edad media de diagnóstico de Lupus de 27.7 ± 8.1 años y de NL de 28.8 años ± 9.3 años; el 16.2% presentó anticuerpos positivos para SAF, el 63.2% presentó HTA al diagnóstico. La mayoría fue NL Clase IV según la biopsia renal. A los 3.6 y 12 meses no se encontró diferencia en la remisión y reactivación entre el grupo de Ciclofosfamida y el del MMF (P

The clinical advantage of targeting index-based remission prior to Boolean remission was evaluated retrospectively. A total of 578 patients with rheumatoid arthritis (RA), who were treated for more than three years, were recruited. Patients who were treated to targeted index-based remission and composite measure remission criteria such as Boolean remission from the first consultation were divided according to the turn of attaining Boolean remission and index-based remission: G-IBR, a group that matched index-based remission at the same time Boolean remission is attained or earlier; G-BR_IF, a group that attained Boolean remission followed by index-based remission or failed; G-IR_BF, a group that could not attain Boolean remission despite attaining index-based remission; G-BothF, a group that failed to attain either Boolean remission or index-based remission. Background factors were statistically compared among groups. The Boolean remission rate in patients who attained index-based remission (BRR) and the rate of failure to attain index-based remission in patients who failed to attain Boolean remission (BFR) were statistically evaluated. Groups comprising 225, 231, and 482 in G-IBR; 160, 154, and 8 in G-BR_IF; 18, 18, and 75 in G-IR_BF; and 175, 175, and 13 in G-BothF when indexing the clinical disease activity index (CDAI), simplified disease activity index (SDAI), and 28-joints disease activity score with C-reactive protein (DAS28-CRP), respectively. Disease activity indices' scores after Boolean remission were demonstrated to be significantly higher in the G-BR_IF group than in the G-IBR group. BRR was 92.6%, 92.8%, and 86.5%, while BFR was 71.3%, 71.3%, and 13.8% when indexing CDAI, SDAI, and DAS28-CRP, respectively. Targeting CDAI and SDAI remission prior to Boolean remission contributes to a stable clinical course. [ABSTRACT FROM AUTHOR]

To evaluate the effectiveness and safety of tocilizumab (TCZ) monotherapy in biologic-naïve patients with rheumatoid arthritis (RA) versus patients with previous biologic exposure in a real-world setting. Non-controlled clinical-trial, 32-week prospective multicenter study including RA patients with moderate-severe disease activity starting TCZ in monotherapy who had a prior inadequate response or were intolerant to methotrexate (MTX). Effectiveness according to EULAR response evaluated at 24-week and safety at 32-weekwere assessed. Of the 93 were enrolled of whom 84 (90%) were eligible for the effectiveness analysis. Biologic-naïve patients (n = 46, 54.8%) were younger (51.5 versus 57.9) with shorter disease duration (6.4 versus 13.3) but presented similar comorbidities in comparison with non-naïve patients. DAS28 remission was achieved in a higher percentage in the group of patients with prior biological treatment. 89 adverse events (AE) were recorded in 50 patients, most of them non-serious AE (non-SAE) (86.3%). In a real world setting, TCZ exhibit similar effectiveness and safety in monotherapy in patients with RA regardless previous exposure to other biologic therapies. This study provides additional and valuable real-world findings on the use of TCZ in patients with RA. [ABSTRACT FROM AUTHOR]

Los impuestos constituyen un recurso económico para poder cubrir el gasto público de un Estado. Por otro lado, la recaudación de impuestos se ve afectada por el incumplimiento de las obligaciones tributarias por parte de los contribuyentes, que, debido a ciertos factores, no realizan su pago a tiempo. Este problema acarrea que el SRI (Servicio de Rentas Internas) no recaude de manera efectiva los recursos económicos, en este sentido, el Estado se ve en la necesidad de expedir leyes que permitan una recaudación ágil y a corto plazo de recursos, como lo es una remisión tributaria. El presente trabajo es un análisis de la remisión tributaria en el Ecuador aplicado en el año 2018, en donde se logró gestionar una recaudación de 1.268 millones en total, lo que corresponde a 351 mil contribuyentes beneficiados. Este análisis se fundamenta en la investigación documental y analítica de la información proporcionada por el SRI, así como la revisión pormenoriza de manuscritos relacionados al tema de investigación, lo que ayudará a determinar el impacto generado en la recaudación de impuestos por la aplicación de este tipo de régimen, qué sectores se beneficiaron de su aplicación, así como si este tipo de leyes son favorables para el Estado.

El nuevo Libro VI pretende fomentar más la aplicación del derecho penal canónico. Hay cánones que tienen claramente este sentido, otros que se han reelaborado con la misma intención, y la redacción procura ser más clara definiendo mejor los pasos que se han de dar. Aumenta el número de delitos (los de índole sexual tienen un importante precedente en el m. p. Vos estis lux mundi), la regulación de la remisión de la pena es más rigurosa, se reducen notablemente las penas facultativas y aumentan los plazos de prescripción. Con todo ello se endurece la disciplina penal con respecto al CIC de 1983. Por otro lado, el derecho penal se hace más aplicable a los laicos y se subraya la exigencia de reparar los daños que pueda generar el delito.

Background and Objective: Psoriasis often precedes the onset of psoriatic arthritis (PsA), so dermatologists often face the challenge of early identifying signs of PsA in patients with psoriasis. Our aim was to validate the Spanish version of the PURE-4 questionnaire as a screening tool for PsA, evaluate its performance in terms of sensitivity, specificity, feasibility, reliability, and build validity., Methods: This was a cross-sectional, observational, multicenter trial of adult patients with psoriasis. Initially, patients were assessed by a dermatologist and completed 2 self-administered versions (in print and online) of the PURE-4 questionnaire. Afterwards, the rheumatologist, blinded to the PURE-4 results, assessed the presence/absence of PsA, being the reference to determine the performance of the PURE-4 questionnaire., Results: A total of 268 patients were included (115 [42.9%] women; mean age, 47.1±12.6). The prevalence of PsA according to rheumatologist diagnosis was 12.7% (34 patients). The mean PURE-4 score for patients with psoriasis diagnosed with PsA was 2.3±1.1, and 1.3±1.3 for patients without PsA (P<.001). The cutoff value ≥2 demonstrated the best performance for detecting PsA, with a negative predictive value of 95.1% (95% confidence interval, 90.3-97.6)., Conclusions: The PURE-4 questionnaire demonstrated good performance in detecting PsA, with an optimal cutoff point ≥2. This simple tool could facilitate early referral of patients to the rheumatology unit., (Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)

La prevalencia creciente de deterioro cognitivo leve (DCL) comórbido con hipertensión arterial (HTA) exige revisión y mejora de las intervenciones disponibles. El objetivo del estudio fue comparar el efecto en las funciones cognitivas de la rehabilitación cognitiva (RC) y otras formas de estimulación. Con un diseño cuasi experimental, se evaluaron cuatro estímulos naturales (actividad física, actividades intelectuales domiciliarias, hobbies, trabajo) de 128 pacientes mayores a 55 años, hipertensos y con deterioro de por lo menos dos áreas de desempeño cognitivo y con deterioro vascular, seleccionados mediante un muestreo por conveniencia. Cuarenta y cuatro de ellos participaron voluntariamente en sesiones de RC. Se compararon los efectos de la RC y de los estímulos naturales sobre cinco funciones cognitivas, tres relativas al lenguaje (denominativo, comprensivo y fluencia verbal) memoria global y atención; valoradas desde el ACE Test (dominios atención, memoria, fluencia verbal y lenguaje), Token Test. La comparación se realizó mediante un modelo multivariado para medidas repetidas con control de variables eventualmente confundidoras. Los principales resultados fueron: menor edad y mayor trayectoria académica predicen un mejor nivel inicial en las funciones evaluadas. La RC se asocia a ganancias en atención, memoria y fluencia verbal. Las actividades intelectuales domiciliarias también muestran efectos positivos. Las mayores ganancias se registran entre quienes tenían mayor deterioro cognitivo y menor trayectoria académica. La postulación de la reserva cognitiva restante sintetizaría estos fenómenos. La principal conclusión es que la RC es la estimulación prioritaria, seguida por actividades intelectuales domiciliarias, para el mantenimiento o recuperación parcial de funciones cognitivas en pacientes con DCL e HTA.

Introducción: las enfermedades glomerulares primarias ocupan la tercera causa de enfermedad renal crónica, siendo el origen más común de síndrome nefrótico en Colombia la nefropatía membranosa (NM). El tratamiento de la NM con ciclofosfamida endovenosa es una opción terapéutica, que no ha sido descrita en nuestra población. Objetivo: determinar la respuesta al tratamiento con ciclofosfamida endovenosa en la NM idiopática en el Hospital de San José de Bogotá en el periodo enero 2000 a enero 2019. Metodología: estudio tipo serie de casos donde se incluyeron todos los pacientes adultos con diagnóstico de NM idiopática por biopsia renal tratados con ciclofosfamida endovenosa en el periodo descrito Resultados: ocho pacientes se incluyeron en el estudio de los cuales 50% eran mujeres, la mediana de edad de presentación fue 32,5 (RIQ:26-45) años. El 100% de los pacientes presentaron remisión parcial o completa, distribuidos así: 62,5% completa y 37,5% parcial. La mediana en el aumento de la tasa de filtración glomerular posterior al uso de ciclofosfamida endovenosa fue 9 (RIQ: 1-20,2) mL/min/1.73 m2. La sobrevida renal fue 100% y el porcentaje de recaída 12,5%. Conclusiones: el uso mensual de ciclofosfamida endovenosa es una opción en el manejo de la NM idiopática con un porcentaje de remisión parcial o completa de 100%, utilizando una dosis mediana acumulada de 93 (RIQ: 65,6-125) mg/k.

The increasing prevalence of mild cognitive impairment (MCI) comorbid with arterial hypertension requests the revision and enhancement of available interventions. The goal of this study was to compare the effect of cognitive rehabilitation (CR) and other forms of stimulation on cognitive functions. Using a quasi-experimental design and a convenience sampling, the reception of four natural stimuli (physical and intellectual activities, hobbies, work) was collected from 128 hypertensive patients aged over 55 years with cognitive (at least two areas) and vascular impairment. Forty-four of them willingly participated in CR sessions. The effects of CR and natural stimuli on five cognitive functions were compared, three related to language (comprehensive, denominative, and fluent language), global memory and attention, assessed with the ACE Test (attention, memory, verbal fluency and language domains). Multivariate modeling analysis for repeated measures was used, controlling for potentially confounding variables. Main results show that younger age and higher academic trajectory predict better initial levels of the evaluated functions. CR is associated with gains in attention, memory and verbal fluency. Written home cognitive activities show also positive effects. The larger gains are observed in participants with higher cognitive impairment and lower academic trajectories. The postulate of the remaining cognitive reserve would synthesize these phenomena. The study concludes that CR is the preferred form of stimulation, followed by home intellectual exercises for the maintenance and partial recovery of cognitive functions in patients with mild cognitive impairment and hypertension. [ABSTRACT FROM AUTHOR]

In Brazil, few studies have investigated the psychological aspects of childhood cancer. The aim of this article was to compare the psychological adjustment of children with cancer from different survival perspectives with that of children without cancer, besides examining potential risk factors. The sample consisted of 179 participants (6-14 years-old) recruited in two Brazilian public hospitals and three schools, and divided in three groups (relapsed, survivors and control). Children answered orally the self-reported Behavior Assessment Scale for Children, the Revised Children's Manifest Anxiety Scale and Piers-Harris' Self-Concept Scale. No differences were found between groups regarding school and clinical maladjustment, personal adjustment, emotional symptoms and self-concept. Findings also showed positive associations between psychological maladjustment and gender, younger age, lower household income, single parenthood and lower levels of parental education. Conclusions indicate that children with cancer adapt well to the disease and do not present more psychological problems than controls. [ABSTRACT FROM AUTHOR]

México es el primer lugar a nivel mundial en obesidad; la Diabetes tipo 2 se encuentra asociada hasta en 90%. Este estudio observacional ambispectivo del 2009 al 2015, compara las tasas de remisión de diabetes tipo 2 en pacientes con IMC >35 kg/m² operados de Bypass Gástrico Laparoscópico (BPGL) vs Gastrectomía Vertical en Manga Laparoscópica (GVML) monitorizando la normalización de los niveles de glucosa plasmática, disminución del porecentaje de HbA1C y cese en el uso de antidiabéticos por lo menos un año, siendo ese su objtetivo. Se analizaron los expedientes clínicos de los pacientes operados de BPGL y GVML con obesidad mórbida y diabetes tipo 2 en el periodo de enero del 2009 a junio del 2015, registrando en una base de datos las variables medibles de cada paciente. Se utilizó una tabla de ANOVA y la prueba t de Student mediante programa de análisis de datos SPSS®. Posterior a la cirugía se registraron cifras de glucosa en ayuno <100 mg/dl desde los primeros tres meses en la mayoría de los pacientes. Después de 12 meses de seguimiento los niveles de glucosa descendieron de 152.16 ± 65.3 mg/dl a 88.16 ± 14.05 mg/dl (p< 0.001), el porcentaje de HbA1C bajó de 7.4 ± 1.4 a 5.3 ± 0.8 (p <0.001), cuatro pacientes continuaron con algún tipo de medicamento, dos con insulina y dos con hipoglucemiantes orales. Existió una remisión de la diabetes tipo 2 en 20 pacientes (80%). En los pacientes con obesidad mórbida y diabetes tipo 2 tratados en el Hospital Central Militar, la GVML y el BPGL han demostrado seguridad y efectividad en la remisión de diabetes tipo 2 a mediano plazo. Sin diferencia significativa entre ambos. [ABSTRACT FROM AUTHOR]

Introducción: el lupus es una enfermedad compleja y varias veces de difícil abordaje. Alcanzar la remisión es uno de los objetivos, incorporando opciones terapéuticas. Objetivos: describir las características generales de los pacientes según el estado de la enfermedad y el uso de belimumab. Materiales y métodos: estudio de corte transversal, registro RELESSAR. Se definió el estado de la enfermedad como: remisión: SLEDAI=0 y sin corticoides; baja actividad de la enfermedad: SLEDAI >0 y ≤4 y sin corticoides; control no óptimo: SLEDAI >4 y cualquier dosis de corticoides. Resultados: se incluyeron 1.277 pacientes, 23,4% en remisión, 12,6% en baja actividad y 63,8% con control no óptimo. En este último grupo eran más jóvenes y con menor duración de la enfermedad; presentaban mayores índices de actividad y cronicidad, y mayor empleo de inmunosupresores. Solo el 22,3% de los pacientes con criterio potencial de uso de belimumab (lupus eritematoso sistémico activo a pesar del tratamiento estándar) lo recibía en ese momento. Las variables asociadas a hospitalizaciones fueron: terapia con corticoides, ciclofosfamida y mayor SLICC. Conclusiones: se refleja la complejidad del manejo de estos pacientes y se visualizan aspectos estructurales como la desigualdad. El uso del belimumab resultaría beneficioso en los pacientes seleccionados.

Background: Faecal calprotectin (FC) shows an excellent correlation with endoscopic and histological activity of ulcerative colitis (UC) and it is the best predictor of clinical relapse. Our aim was to evaluate the usefulness of modifying the dose of mesalazine based on FC levels, in clinical practice., Methods: Retrospective, single-centre study in UC patients in clinical remission while treated with mesalazine which dosage was decreased (DOWN) or increased (UP) according to FC levels. The main endpoint was the long-term maintenance of clinical remission., Results: A total of 56 patients were included (39 DOWN, 17 UP). In the DOWN group, the median baseline dose of mesalazine was 3.6g/day and the median baseline FC was 36μg/g. After a median follow-up of 22 months, 28% required rescue therapy. The cumulative relapse-free survival after tapering was 91% and 82% at 12 and 24 months, respectively. In the UP group, the median baseline dose of mesalazine was 2.4g/day, with a median baseline FC of 524μg/g. After a median follow-up of 12 months, 29% required rescue therapy. The cumulative relapse-free survival after dose increase was 86% and 72% at 12 and 24 months, respectively., Conclusions: Mesalazine dose modification based on FC monitoring seems to be a safe strategy in patients with UC in clinical remission, with a probability of clinical relapse around 20% at two years., (Copyright © 2023 Elsevier España, S.L.U. All rights reserved.)

We aimed to reach a consensus on the best instruments to monitor disease activity in patients with psoriatic arthritis (PsA) and to develop a consensus definition of remission. A modified Delphi approach was used. A scientific committee provided statements addressing the definition of remission and the monitoring of PsA in clinical practice. The questionnaire was evaluated in 2 rounds by rheumatologists with experience in managing PsA patients. A panel of 77 rheumatologists reached agreement on 62 out of the 86 proposed items (72.0%). The most recommended index for monitoring disease activity was DAPSA (cut-off values: ≤4 for remission and >4–14 for low disease activity ([LDA]), MDA (at least 5/7 criteria). In cases with axial involvement, ASDAS was the preferred index (cut-off values: <1.3 for remission and <2.1 for LDA). BASDAI (cut-off values: ≤2 for remission and ≤4 for LDA) may be used as an alternative. PsAID was the preferred tool to assess disease impact. We propose a definition of remission in PsA as the absence of disease activity evaluated by DAPSA or MDA (ASDAS and/or BASDAI in patients with axial involvement), which would imply absence of signs or symptoms of inflammation, physical well-being, lack of disease impact, and absence of inflammation as measured by biological markers. [ABSTRACT FROM AUTHOR]

Introducción: las adenopatías se definen como anormalidades en tamaño y consistencia de los ganglios linfáticos y son una causa frecuente de consulta en el rango poblacional de 3 a 5 años. Su diagnóstico depende del historial médico, sus características, la presencia de síntomas constitucionales y los estudios de extensión. Objetivo: conocer la pertinencia de la remisión de niños con adenopatías al servicio de hemato-oncología pediátrica, describiendo las características clínicas y paraclínicas de los casos, además de los predictores de malignidad. Métodos: se realizó una revisión y caracterización de historias clínicas de pacientes remitidos por primera vez a consulta de hemato-oncología pediátrica por presentar adenopatías, se determinó la asociación estadística de pertinencia de la remisión según criterios establecidos en la literatura. Resultados: se evaluaron las historias clínicas de 136 pacientes remitidos a consulta de hemato-oncología pediátrica por presentar adenopatías, el tiempo de evolución fue mayor a ocho semanas en el 81,62% de los casos. En 98 pacientes (72,06%) las adenopatías correspondieron a adenomegalias reactivas/benignas y sólo en dos casos correspondieron a neoplasias (1,47%). La asimetría fue el criterio con significancia estadística OR 3,45 (IC 1,51-7,86) relacionado con pertinencia de la remisión, adicional a los descritos de la literatura. Conclusiones: deben considerarse para remisión pertinente al servicio de hematooncología los pacientes con adenopatías en localizaciones patológicas, de tamaño mayor a 2 cms, asimétricas, asociadas a síntomas constitucionales, con citopenia en el hemograma y ecografía de la lesión sospechosa que describa el hilio graso.

Palindromic rheumatism (PR) is characterized by repetitive, afebrile episodes of acute arthritis and peri-arthritis. The aim of this study was considering the long-term outcomes of patients with PR who were treated with tight control strategy using Disease-modifying anti-rheumatic drugs (DMARDs). We reviewed the charts of 106 patients diagnosed with PR who were referred to the Connective Tissue Diseases Research Center (CTDRC). We recruited all the patients diagnosed with PR according to the criteria of Hannonen. They visited the CTDRC clinic regularly and were treated with hydroxychloroquine and low dose prednisolone because of active episodes of PR. In cases that the attacks did not come under control in 3–6 months, methotrexate was added or replaced and the dose was increased up to 25 mg/week. In resistant cases, sulfasalazine was added, followed by the addition of leflunomide and then azathioprine. Disease outcome was evaluated by getting complete or partial remission and prevention of disease evolution to rheumatoid arthritis (RA) or other inflammatory connective tissue diseases. This study included 92 patients with PR who were treated with DMARDs. Attacks were controlled completely or partially in 76 (82.6%) patients. Medications free remission was obtained in 16.3% of the patients. RA developed in 8.7% of the patients. By multivariate logistic regression analysis, age ≤40 at disease presentation, non-adherence to therapy and PIP joints involvement were the only factors which independently predicted the risk of treatment failure. Tight control strategy by using DMARDs may control PR and prevent disease progression to RA. [ABSTRACT FROM AUTHOR]

Copyright of Revista de la ALAD is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Rheumatoid arthritis (RA) is the most frequent chronic polyarthritis. The current goal of RA treatment is to achieve clinical remission. The goal of this study was to determine the prevalence of remission in a cohort of patients from clinical practice, and to identify potentially modifiable factors associated with remission. A retrospective study was performed on a cohort of RA patients seen at the first consultation at the HUGC Rheumatology Service Dr. Negrín (HUGCDN) between first of January 2000 and thirtieth of April 2014. Sustained remission was defined as DAS28 less than 2.6 in the last two available visits in the medical history. A total of 463 patients were consecutively included, most (75%) women, with a mean age at the onset of RA of 50 years and a mean duration of the disease at follow-up of 8 years. 46% of the patients achieved sustained remission. Multiple logistic regression analyses found male sex (P =.031, OR 1.7, 95% CI 1.05–2.82), diagnosis in the first year of symptoms (P =.023, OR 1.7, 95% CI 1.07–2.69) and the initial DAS28 (P =.035) to be independent predictors for sustained remission. The 46% of the patients with RA followed in the HUGC Dr. Negrín are in persistent remission, being the early diagnosis a modifiable factor predictor of remission. Thus, an objective of the Rheumatology Service should be to improve the diagnostic delay of RA in the health area. [ABSTRACT FROM AUTHOR]

Copyright of Adicciones is the property of Sociedad Cientifica Espanola de Estudios sobre el Alcohol and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Evaluation of one's own body highly depends on psychopathology. In contrast to healthy women, body evaluation is negative in women from several diagnostic groups. Particularly negative ratings have been reported in disorders related to childhood sexual abuse (CSA) including borderline personality disorder (BPD). However, it is unknown whether this negative evaluation persists beyond symptomatic remission, whether it depends on the topography of body areas (sexually connoted versus neutral areas), and whether it depends on CSA. First, we aimed at a quantitative comparison of body evaluation across three diagnostic groups: current BPD (cBPD), remitted BPD (rBPD), and healthy controls (HC). Second, we aimed at clarifying the potentially moderating role of a history of CSA and of the sexual connotation of body areas. The study included 68 women from the diagnostic groups of interest (cBPD, rBPD, and HC). These diagnoses were established with the International Personality Disorder Examination. The participants used the Survey of Body Areas to quantify the evaluation of the own body and the Childhood Trauma Questionnaire for assessing CSA. While the evaluation of the own body was generally negative in women from the cBPD group it was positive in those who had remitted from BPD. However, their positive scores were strictly confined to neutral body areas, whereas the evaluation of sexually connoted body areas was negative, resembling the respective evaluation in cBPD patients and contrasting the positive evaluation of sexually connoted areas in healthy women. The negative evaluation of sexually connoted areas in remitted women was significantly related to a history of CSA. Women with BPD may require a specifically designed intervention to achieve a positive evaluation of their entire body. The evaluation of sexually connoted body areas seems to remain an issue even after remission from the disorder has been achieved. [ABSTRACT FROM AUTHOR]

Copyright of Archivos Latinoamericanos de Nutrición is the property of Sociedad Latinoamericana de Nutricion and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

To identify synovitis and tenosynovitis active by using the Ultrasound 7 (US 7) scoring system in patients with rheumatoid arthritis (RA) in clinical remission induced by synthetic disease-modifying antirheumatic drugs (DMARDs). This is a multicentric, cross-sectional, observational study including 94 RA patients >18 years old who were in remission as defined by the 28-joints disease activity score (DAS28) <2.6 induced by synthetic DMARD during at least 6 months. Patients with a previous or current history of biologic DMARD treatment were not included in the study. Demographic and clinical data were collected by the local rheumatologist; the US evaluation was performed by a calibrated rheumatologist, who intended to detect grayscale synovitis and power Doppler (PD) using the 7-joint scale. Intra and inter-reader exercises of images between 2 ultrasonographers were realized. Patients' mean age was 49.1 ± 13.7 years; 83% were women. The mean disease duration was 8 ± 7 years and remission lasted for 27.5 ± 31.8 months. The mean DAS28 score was 1.9 ± 0.66. Grayscale synovitis was present in 94% of cases; it was mild in 87.5% and moderate in 12.5%. Only 12.8% of the patients had PD. The metatarsophalangeal, metacarpophalangeal, and carpal joints of the dominant hand were the joints more frequently affected by synovitis. Tenosynovitis by grayscale was observed in 9 patients (9.6%). The intra and inter-reading kappa value were 0.77, p < 0.003 (CI 95%, 0.34–0.81) and 0.81, p < 0.0001 (CI 95%, 0.27–0.83) respectively. Low percentage of synovitis and tenosynovitis active were founded according to PD US by 7 score in RA patients under synthetic DMARDs during long remission. This score has benefit because evaluate tenosynovitis, another element of subclinical disease activity. [ABSTRACT FROM AUTHOR]

El objetivo fue evaluar la prevalencia de tenosinovitis detectada por ecografía-doppler en pacientes con Artritis Reumatoidea (AR) en remisión clínica sostenida, determinar su asociación con las características de la enfermedad y determinar si la presencia de tenosinovitis ecográfica podría agregar información a la sinovitis para definir remisión ecográfica.

Introduction: Nephritis is the most common of all serious manifestations of SLE. The proliferative forms require immunosuppressive treatment, but responses are not consistent and exacerbations are frequent during or after the treatment has been completed. Methods: We retrospectively analyzed the evolution of a cohort of 84 patients with proliferative lupus nephritis with immunosuppressive treatment, in a long-term (up to 203 months) follow up. Were taken as basal: sex, age, latency between onset and diagnosis of SLE nephritis, serum complement, plasmatic creatinine and proteinuria. We evaluated: initial response to therapy, occurrence of relapse or recurrence and score at the end of the observation period. Results: Remission of initial nephritis was seen in 73% of the cases, although at the end of monitoring only 54% of patients were in remission. 45 patients had one episode of nephritis, 32 patients had two, and 7 patients had three. Most of the remissions took place during the maintenance period. Complete remission had better evolution than partial remission. High serum creatinine levels and proteinuria at baseline were indicators of bad prognosis. Oral Azathioprine was more effective than quarterly IV Cylophosphamide as maintenance therapy, despite of a high incidence of relapses. Mycophenolate was not more effective than Cyclophosphamide/azathioprine for the treatment of relapses or recurrences. Conclusions: Our results are similar to the literature. Extended follow up enables the evaluation of the long term result of the initial symptoms, any possible future outbreaks, the effectiveness of the treatment and its evolution after its interruption.

Copyright of Cirugía y Cirujanos is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: Crohn's disease (CD) affects Health Related Quality of Life (HRQoL) especially in patients with clinical activity but their impact over the disease during periods of remission has not been sufficiently studied. Objective: To evaluate HRQoL in CD patients in remission and to identify socio-demographic and clinical factors related. Methods: We included patients with CD in remission for at least 6 months, defined as a CDAI < 150 and a CRP < 5 mg/L. Socio-demographic and clinical parameters were recorded. HRQoL was evaluated with Short Form 36 Questionnaire (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ). Results were analyzed using multiple regressions with a confidence interval of 95%. Results: Nine two patients (X = 37 ± 11.4 years, 52.2% men) were consecutively included. Two patients failed to fill correctly the questionnaire and were excluded. Scores on the SF-36 were lower than in the general population of similar age and sex. The most affected dimension in the SF-36 was General Health (47.98 ± 19.58) and the IBDQ Systemic Symptoms (5.15 ± 1.27). Age, colonic location and previous surgery was related with worse HRQoL, while higher educational status, more time since diagnosis, steroid-resistance and inflammatory behavior, was associated with better HRQoL. Conclusions: Despite being in remission, CD patients had affected their HRQoL, so we must continue working to achieve improvement in HRQL of these patients during these periods of the disease.Introducción: La enfermedad de Crohn (EC) afecta la Calidad de Vida Relacionada con la Salud (CVRS) en las fases de actividad pero el impacto de esta enfermedad en la CVRS durante los períodos de remisión no ha sido suficientemente estudiada. Objetivo: Evaluar la CVRS en pacientes con EC en remisión e identificar los factores sociodemográficos y clínicos relacionados. Métodos: Se incluyeron pacientes adultos con EC en remisión durante al menos 6 meses, definida con un CDAI < 150 y una PCR < 5 mg/l. Se recogieron datos sociodemográficos, clínicos y de CVRS con los cuestionarios Short Form 36 Questionnaire (SF-36) y The Inflammatory Bowel Disease Questionnaire (IBDQ). Los resultados fueron analizados mediante regresión múltiple con un intervalo de confianza del 95%. Resultados: Se incluyeron consecutivamente 92 pacien-tes (X = 37 ± 11,4 años; 52,2% varones). 2 pacientes no cumplimentaron adecuadamente los cuestionarios. Las puntuaciones en el SF-36 fueron inferiores a las de la población general de similar edad y sexo. La dimensión más afectada en el SF-36 fue Salud General (47,98 ±19,58) y en el IBDQ Síntomas Sistémicos (5,15 ± 1,27). La mayor edad, la localización colónica y la cirugía previa se relacionaron con una peor CVRS, mientras que mayor nivel de estudios, mayor tiempo desde el diagnóstico, patrón inflamatorio y corticorresistencia se asociaron con una mejor CVRS. Conclusiones: A pesar de encontrarse en período de remisión los pacientes EC presentan afectada su CVRS, por lo que se debe continuar trabajando en la consecución de la mejora en la CVRS de estos enfermos durante esta fase de la enfermedad.

Objetivo: Determinar el impacto de la comorbilidad, el uso de recursos y los costes (sanitarios y en pérdidas de productividad laboral) en el mantenimiento de la remisión de la depresión en un ámbito poblacional español. Métodos: Diseño observacional, prospectivo, multicéntrico, realizado con bases de datos poblacionales. Los criterios de inclusión fueron: edad >18 años, inicio del episodio depresivo entre enero de 2003 y marzo de 2007, prescripción de antidepresivos >60 días después de la primera prescripción y duración del seguimiento de 18 meses (estudio: 12 meses; continuación: 6 meses). Se consideraron 2 subgrupos: pacientes en remisión y sin remisión. Las principales mediciones fueron sociodemográficas, episodios, bandas de utilización de recursos, costes sanitarios (directos) y en pérdidas de productividad (indirectos). Se realizó análisis de regresión logística y de análisis de la covarianza (ajuste Bonferroni). Resultados: Se reclutaron 4.572 sujetos. El 54,6% (intervalo de confianza del 95%: 53,2-56,0%) se consideraron en remisión. Los pacientes en remisión mostraron menor edad (52,6 frente a 60,7 años), mayor proporción de mujeres (71,7% frente a 78,2%), más morbilidad general (6,2 frente a 7,7 episodios/año), menos bandas de utilización de recursos/año (2,7 frente a 3,0), menor incapacidad laboral (31,0 frente a 38,5 días) y menor duración del tratamiento antidepresivo (146,6 frente a 307,7 días); pObjective: To determinate the impact of comorbidity, resource use and cost (healthcare and lost productivity) on maintenance of remission of major depressive disorder in a Spanish population setting. Methods: We performed an observational, prospective, multicenter study using population databases. The inclusion criteria were age >18 years, first depressive episode between January 2003 and March 2007, with antidepressant prescription >60 days after the first prescription and a follow-up of at least 18 months (study: 12 months; continuation: 6 months). Two subgroups were considered: patients with/without remission. Main measures: sociodemographic data, episodes, resource utilization bands, healthcare costs (direct) and lost productivity (indirect). Logistic regression and analysis of covariance (Bonferroni correction) were used for analysis. Results: A total of 4,572 patients were analyzed and 54.6% (95% confidence interval: 53.2-56.0%) were considered in remission. Patients in remission were younger (52.6 vs. 60.7), with a lower proportion of women (71.7% vs. 78.2%), and showed less general morbidity (6.2 vs. 7.7 episodes/year), lower resource utilization bands/year (2.7 vs. 3.0), fewer sick leave days (31.0 vs. 38.5) and shorter treatment duration (146.6 vs. 307.7 days); p

Se estudió la supervivencia de 201 pacientes a quienes se les diagnosticó un carcinoma broncógeno (155 con carcinoma de células no pequeñas y 46 con carcinoma de células pequeñas) y recibieron tratamiento oncoespecífico, en sus diferentes modalidades, entre el año 1997 y el 2002. Se describió la muestra y se analizó la supervivencia mediante el método de Kaplan Meier en función de variables como edad, estirpe histológica, estadio clínico y tratamiento empleado. Se halló que la supervivencia global de los pacientes incluidos en el estudio fue de 15 %. La probabilidad de sobrevivir a los 5 años fue de 18,5 %, para el carcinoma de pulmón de células no pequeñas. Los principales factores predictores pronósticos de la enfermedad fueron los estadios potencialmente curables (I y II) en el momento del diagnóstico con la posibilidad de recibir tratamiento quirúrgico. La edad no influyó significativamente en la supervivencia. La utilización de quimio-radioterapia, como régimen adyuvante a la cirugía mejoró la supervivencia de los pacientes operados. La supervivencia media a los 5 años lograda en los pacientes con carcinoma indiferenciado de células pequeñas fue de 4,5 %.Survival from 201 patients was studied, which were diagnosed with bronchogenic carcinoma (155 with non-small cell carcinoma and 46 with small cell carcinoma) different modalities of specific oncotherapy from 1997 to 2002. Sample was described and the survival was analyzed by Kaplan Meier method according to variables including age, histological lineage, clinical status and treatment used. We noted that 5-years global survival was of 18,5% for non-small cells lung carcinoma. Main predisposing factors of disease were the probability of surgical treatment. Use of chemotherapy as surgery adjuvant regime improves survival of patients operated on. 5-years mean survival achieved in patients presenting with in small cells non-differentiated carcinoma was of 4,5%.

Introducción: el papel de la ansiedad y depresión en pacientes con enfermedad de Crohn (EC) en remisión es incierto. Objetivo: evaluar la frecuencia de ansiedad y depresión en pacientes con EC en remisión y potenciales factores que pueden influir en el desarrollo de esos síntomas. Métodos: se incluyeron pacientes con EC mayores de 18 años, que estuviesen en remisión durante al menos 6 meses. La remisión se definió como un CDAI < 150 junto con una PCR < 5 mg/l. Se recogieron datos sociodemográficos y los pacientes fueron estratificados clínicamente y se evaluó el tratamiento empleado para el mantenimiento de la remisión. Los síntomas ansiosos y depresivos se evaluaron a través de la Hospital Anxiety and Depression Scale (HAD). Los resultados fueron analizados mediante regresión logística y se muestran como Odds ratio con un intervalo de confianza del 95%. Resultados: se incluyeron 92 pacientes (48 hombres, edad media 37, rango 18 a 71 años). Un paciente no completó correctamente el cuestionario. Se encontraron síntomas ansiosos y depresivos en 36 (39%) y 22 (24%) pacientes respectivamente. El tratamiento con infliximab de mantenimiento fue el único factor asociado con ansiedad (OR = 3,11; 95% IC: 1,03-9,43; p < 0,05). Por el contrario, la presencia de síntomas depresivos es menos frecuente en pacientes en tratamiento de mantenimiento con infliximab (OR = 0,16; 95% IC: 0,02-0,97; p < 0,05). Conclusiones: a pesar de estar en remisión clínica, un importante número de pacientes con EC presentas síntomas ansiosos o depresivos. El tratamiento con infliximab parece asociarse con más ansiedad pero menos síntomas depresivos. Probablemente algunos de estos pacientes serían susceptibles de tratamiento psicológico.Background: the role of anxiety and depression in CD patients in remission has been poorly investigated. Objective: the aim of the study was to evaluate the frequency of anxiety and depression symptoms in CD patients in remission, and potential factors influencing the development of these symptoms. Methods: CD patients older than 18 years in remission for at least 6 months before study entry were included. CD remission was defined as a Crohn's disease Activity Index (CDAI) < 150 points together with C-reactive protein < 5 mg/L. A demographic questionnaire was filled in, and all patients were clinically classified. The therapy maintaining remission was also recorded. A Hospital Anxiety and Depression scale (HAD) was administered to all patients. Results are shown as OR and 95% CI, and analyzed by logistic regression. Results: 92 consecutive patients were included (48 male, mean age 37 years, range from 18 to 71 years). One patient failed to correctly fill in the questionnaire. Anxiety and depression symptoms were present in 36 (39%) and 22 (24%) patients, respectively. Infliximab therapy was the only factor associated with anxiety (OR = 3.11; 95% CI: 1.03-9.43; p < 0.05). In contrast, the presence of depressive symptoms is less frequent in patients under infliximab therapy (OR = 0.16; 95% CI: 0.02-0.97; p < 0.05). Conclusions: despite clinical remission, an important number of CD patients present with anxiety or depressive symptoms. Infliximab therapy in CD patients is associated to more anxiety but fewer depressive symptoms. CD patients in remission would probably benefit from psychological support.

Introduction: Idiopathic generalized epilepsies (IGI) are an electroclinical syndrome that includes four subsyndromes according to the ILAE 2017 classification. The long-term prognosis of these syndromes is uncertain due to the scarcity and heterogeneity of the studies. The objective of this study is to analyze the long-term prognosis of these syndromes, pharmacological treatment and the seizure recurrence., Method: Observational and retrospective study of a serie of patients diagnosed with EGI. Epidemiological variables, pharmacological treatment, freedom of seizures and recurrence after withdrawal of treatment were collected., Results: We included 101 patients, the majority women (56.4%), with a median evolution of epilepsy of 17 years (interquartile range: 7-31). The most frequent syndrome was juvenile myoclonic epilepsy (46.5%), followed by epilepsy with generalized tonic-clonic seizures alone (25.7%), juvenile absence epilepsy (13.9%) and childhood absence epilepsy (13.9%). The 71.29% were on monotherapy and 20.79% on polytherapy, with significant differences between the different syndromes (P=.001). The most widely used drug was valproic acid. 39.6% presented seizure remission at 5 years, but we did not observe significant differences between the different syndromes (P=.982). The recurrence rate was 71.4% after withdrawal of treatment., Conclusion: Juvenile myoclonic epilepsy was the most frequent subtype of IGE. We observed significant differences in terms of polytherapy in the different syndromes, although not in the rates of remission of seizures at one year and at five years. The majority of patients with treatment withdrawal relapsed., (Copyright © 2022 Elsevier España, S.L.U. All rights reserved.)

Introduction: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), belongs to the group of inflammatory disease of the central nervous system with a predilection for the pontine structures. Case report: Herein we present a case of a Mexican patient clinically and radiologically with excellent response to steroids and inmunomodulatory therapy. Conclusion: There exist less tan 100 reported cases of CLIPPERS worldwide. In this paper systematic literature research is also provided. [ABSTRACT FROM AUTHOR]

BACKGROUND: The clinical disease activity index (CDAI) with 28 joint counts measures the activity of rheumatoid arthritis (RA) without laboratory tests. OBJECTIVE: To evaluate the CDAI in daily practice in RA patients at one year of the symptoms onset. MATERIAL AND METHOD: A prospective study was done with 120 consecutive patients with early RA ≤ 12 months (101 women, 19 men) seen in the rheumatology consult within 1 year of symptoms onset. The CDAI was divided into four categories: high or severe activity >22, moderate >10-22, mild <10 and remission ≤2.8. Functional disability (HAQ, health assessment questionnaire, 0-3 score) was also evaluated. A combination of methotrexate and sulfasalazine or chloroquine and low-dose prednisone 2.5-5.0 mg/d was administered. RESULTS: At baseline, 88 (73%) patients had high activity and 32 (27%) had moderate-mild activity. At 6 months 3% had high activity, whereas 96 (80%) were in remission (median 0, range 0-2.6). At 12 months, 110 patients (91%) were in remission and 6 (5%) had mild activity. The median score of HAQ was 1.4 (range 0.5-3.0) and at 12 months was 0 (range 0-1.2) There was a good correlation between HAQ and CDAI. CONCLUSION: The CDAI score is a clinical tool that omits laboratory tests. Remission, defined as a CDAI ≤2.8 was achieved so early as 6 months. This study also showed improvement in functional ability. [ABSTRACT FROM AUTHOR]